Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Vipoma 1Sarcoma 1Prostatic Neoplasms 1Lymphoma 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

Octreotide 4vatalanib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Melphalan 1Leucovorin 1Irinotecan 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Everolimus 1Disulfides 1Capecitabine 1Biological Therapy 1Bevacizumab 1Acetates 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vipoma × Acetates × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡